<DOC>
	<DOCNO>NCT01038349</DOCNO>
	<brief_summary>The goal study enable study sponsor assess impact market validate blood test physician ' clinical treatment decision make treat RA patient take methotrexate . Ultimately , blood test allow treat physician modify current methotrexate therapy partially respond Rheumatoid Arthritis ( RA ) patient ' therapy , individualized basis , mean improve clinical outcome . The study require blood sample RA patient methotrexate therapy minimum 3 month inadequate response therapy . Physicians provide result test indicate methotrexate polyglutamate ( active metabolite methotrexate ) level patient 's red blood cell mean help determine whether patient 's exposure methotrexate optimize .</brief_summary>
	<brief_title>Applications Methotrexate Optimization Rheumatoid Arthritis</brief_title>
	<detailed_description>This study currently enrol individual establish diagnosis RA receive methotrexate part therapy . Patients required submit blood sample . There cost volunteer participate .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Able read , understand , sign inform consent form Able read , write , speak English â‰¥18 year age Diagnosed RA within past 24 month ( waiver ) Taking oral methotrexate therapy minimum 3 month Considered insufficient response methotrexate therefore candidate change therapy , include change MTX dose change route delivery , add switching DMARDs ( include limit biologic DMARDs ) Prior exposure study center , study physician study patient Avise PG laboratory test Patients know abnormal hepatic hematological parameter Use prednisone &gt; 10mg/day ( equivalent ) Rheumatologic diagnosis primary RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>